BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38712934)

  • 21. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
    Avery LM; Nicolau DP
    Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae.
    Yu W; Luo Q; Shen P; Chen Y; Xu H; Xiao Y; Qiu Y
    Int J Antimicrob Agents; 2021 Dec; 58(6):106458. PubMed ID: 34706255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Li X; Chen Z; Jiao J; Wang S; Wang Y; Wu W; Yang H; Lou H
    Expert Rev Anti Infect Ther; 2023 Jan; 21(1):91-98. PubMed ID: 36433637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F; Zhou Q; Yang X; Bai Y; Cui J
    PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
    Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
    mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.
    Vásquez-Ponce F; Dantas K; Becerra J; Melocco G; Esposito F; Cardoso B; Rodrigues L; Lima K; de Lima AV; Sellera FP; Mattos R; Trevisoli L; Vianello MA; Sincero T; Di Conza J; Vespero E; Gutkind G; Sampaio J; Lincopan N
    Microbiol Spectr; 2022 Oct; 10(5):e0115922. PubMed ID: 35980188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
    Manning N; Balabanian G; Rose M; Landman D; Quale J
    Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
    J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
    Romanelli F; De Robertis A; Carone G; Dalfino L; Stufano M; Del Prete R; Mosca A
    New Microbiol; 2020 Jul; 43(3):136-138. PubMed ID: 32596740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
    Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
    Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
    Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
    Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales.
    Romina PE; Lucía A; Leticia C; Federica F; Pablo Á; Verónica S; Antonio G; Inés B; Rafael V
    J Glob Antimicrob Resist; 2023 Dec; 35():62-66. PubMed ID: 37611893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of
    Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
    Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.